DE

470.26

-1.59%↓

FDX

245.41

+1.56%↑

PAYX

155.09

+0.39%↑

CPRT

57.56

+0.61%↑

HEICA

212.9

+0.18%↑

DE

470.26

-1.59%↓

FDX

245.41

+1.56%↑

PAYX

155.09

+0.39%↑

CPRT

57.56

+0.61%↑

HEICA

212.9

+0.18%↑

DE

470.26

-1.59%↓

FDX

245.41

+1.56%↑

PAYX

155.09

+0.39%↑

CPRT

57.56

+0.61%↑

HEICA

212.9

+0.18%↑

DE

470.26

-1.59%↓

FDX

245.41

+1.56%↑

PAYX

155.09

+0.39%↑

CPRT

57.56

+0.61%↑

HEICA

212.9

+0.18%↑

DE

470.26

-1.59%↓

FDX

245.41

+1.56%↑

PAYX

155.09

+0.39%↑

CPRT

57.56

+0.61%↑

HEICA

212.9

+0.18%↑

Search

Ocugen Inc

Fechado

0.68 6.25

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.62

Máximo

0.7

Indicadores-chave

By Trading Economics

Rendimento

-910K

-14M

Vendas

-372K

764K

EPS

-0.05

Margem de lucro

-1,816.754

Funcionários

95

EBITDA

-603K

-13M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+926.15% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

57M

233M

Abertura anterior

-5.57

Fecho anterior

0.68

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Ocugen Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

8 de abr. de 2024, 14:32 UTC

Grandes Movimentos do Mercado

Ocugen Gets FDA Clearance for IND Amendment for OCU400

Comparação entre Pares

Variação de preço

Ocugen Inc Previsão

Preço-alvo

By TipRanks

926.15% parte superior

Previsão para 12 meses

Média 6.67 USD  926.15%

Máximo 8 USD

Mínimo 4 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Ocugen Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

3 ratings

3

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

0.6351 / 0.7995Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.